Drug interactions among the antiretrovirals

Current Infectious Disease Reports

Volumn 6, Issue 2, 2004, Pages 159-162

  McNicholl, Ian R ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

14 HYDROXYCLARITHROMYCIN; AMPRENAVIR; AMPRENAVIR PHOSPHATE; ANTIRETROVIRUS AGENT; ATAZANAVIR; CIMETIDINE; CLARITHROMYCIN; DIDANOSINE; EFAVIRENZ; ESOMEPRAZOLE; FAMOTIDINE; HISTAMINE H2 RECEPTOR ANTAGONIST; INDINAVIR; LANSOPRAZOLE; LOPINAVIR PLUS RITONAVIR; NIZATIDINE; OMEPRAZOLE; PANTOPRAZOLE; PROTON PUMP INHIBITOR; RABEPRAZOLE; RANITIDINE; RITONAVIR; SILDENAFIL; TENOFOVIR; VARDENAFIL;

AREA UNDER THE CURVE; CONSULTATION; DRUG APPROVAL; DRUG BLOOD LEVEL; DRUG DOSE REDUCTION; DRUG DOSE REGIMEN; DRUG EFFICACY; DRUG ELIMINATION; DRUG HALF LIFE; DRUG METABOLISM; DRUG POTENTIATION; FOOD AND DRUG ADMINISTRATION; GASTROESOPHAGEAL REFLUX; HEALTH PRACTITIONER; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; PATIENT CARE; PATIENT COUNSELING; PHARMACIST; PUBLISHING; REVIEW; UNITED STATES; ZOLLINGER ELLISON SYNDROME;

EID: 3142764628     PISSN: 15233847     EISSN: None     Source Type: Journal    
DOI: 10.1007/s11908-996-0013-9     Document Type: Review

References (21)

1. Dresser GK, Spence JD, Bailey DG: Pharmacokinetic-pharmacodynamic consequences and clinical relevance of cytochrome P450 3A4 inhibition. Clin Pharmacokinet 2000, 38:41-57.
2. De Wildt SN, Kearns GJ, Leeder JS, van den Anker JN: Cytochrome P450 3A, ontogeny and drug disposition. Clin Pharmacokinet 1999, 37:485-505.
3. Gibbs MA, Hosea NA: Factors affecting the clinical development of cytochrome P450 3A substrates. Clin Pharmacokinet 2003, 42:969-986.
4. Michalets EL: Update: clinically significant cytochrome P-450 drug interactions. Pharmacotherapy 1998, 18:84-112.
5. Piscitelli SC, Gallicano KD: Interactions among drugs for HIV and opportunistic infections. N Engl J Med 2001, 344:984-996.
6. Huisman MT, Smit JW, Schinkel AH: Significance of P-glycoprotein for the pharmacology and clinical use of HIV protease inhibitors. AIDS 2000, 14:237-242.
7. Gerber JG: Using pharmacokinetics to optimize antiretroviral drug-drug interactions in the treatment of human immunodeficiency virus infection. Clin Infect Dis 2000, 30 (Suppl 2): S123-S129.
8. Lin JH, Yamazaki M: Role of P-glycoprotein in pharmacokinetics: clinical implications. Clin Pharmacokinet 2003, 42:59-98.
9. Reyataz. Package insert. Princeton, NJ: Bristol-Myers Squibb Company; 2003.
10. Prilosec. Package insert. Wilmington, DE: AstraZeneca; 2000.
11. Nexium. Package insert. Wilmington, DE: AstraZeneca; 2003.
12. Protonix. Package insert. Philadelphia, PA: Wyeth-Ayerst Company; 2003.
13. Prevacid. Package insert. Lake Forest, IL: TAP Pharmaceuticals Inc.; 2003.
14. Aciphex. Package insert. Titusville, NJ: Janssen Pharmaceutica Inc.; 2003.
15. Kaul S, Bassi K, Damle B, et al.: Pharmacokinetic evaluation of the combination of atazanavir (ATV), enteric coated didanosine (ddI-EC), and tenofovir disoproxil fumarate (TDF) for a once-daily antiretroviral regimen [abstract A-1616]. Paper presented at the 43rd Interscience Conference on Antimicrobial Agents and Chemotherapy. Chicago, IL, September 14-17, 2003.
16. Taburet AM, Piketty C, Gerard L, et al.: Pharmacokinetic parameters of atazanavir/ritonavir when combined to tenofovir in HIV-infected patients with multiple treatment failures: a sub-study of Puzzle2-ANRS 107 trial [abstract 537]. Paper presented at the 10th Conference on Retroviruses and Opportunistic Infections. Boston, MA, February 10-14, 2003.
17. Lexiva. Package insert. Research Triangle Park, NC: GlaxoSmith-Kline Inc.; 2003.
18. Kashuba ADM, Tierney C, Downey GF, et al.: Combining GW433908 with lopinavir/ritonavir in HIV-1 infected adults results in substantial reductions in amprenavir and lopinavir concentrations: pharmacokinetic results from adult ACTG protocol A5143 [abstract H-855a]. Paper presented at the 43rd Interscience Conference on Antimicrobial Agents and Chemotherapy. Chicago, IL, September 14-17, 2003.
19. Wire MB, Preston SL, Ballow C, et al.: An assessment of plasma amprenavir pharmacokinetics following administration of two GW433908 and ritonavir QD regimens in combination with efavirenz in healthy adult subjects (APV10009) [abstract 1737]. Paper presented at the 41st Interscience Conference on Antimicrobial Agents and Chemotherapy. Chicago, IL, September 22-25, 2001.
20. Levitra. Package insert. Research Triangle Park, NC: GlaxoSmith-Kline Inc.; 2003.
21. Mummaneni V, Randall D, Chabuel D, et al.: Steady state pharmacokinetic (PK) interaction study of atazanavir (ATV) with clarithromycin (CLR) in healthy subjects [abstract H-1717]. Paper presented at the 42nd Interscience Conference on Antimicrobial Agents and Chemotherapy San Diego, CA, September 27-30, 2002.